List of Certara D360 Customers
Radnor, 19087, PA,
United States
Since 2010, our global team of researchers has been studying Certara D360 customers around the world, aggregating massive amounts of data points that form the basis of our forecast assumptions and perhaps the rise and fall of certain vendors and their products on a quarterly basis.
Each quarter our research team identifies companies that have purchased Certara D360 for Laboratory Management from public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources, including the customer size, industry, location, implementation status, partner involvement, LOB Key Stakeholders and related IT decision-makers contact details.
Companies using Certara D360 for Laboratory Management include: Pfizer, a United States based Life Sciences organisation with 81000 employees and revenues of $63.63 billion, Boehringer Ingelheim, a Germany based Life Sciences organisation with 54500 employees and revenues of $28.94 billion, AstraZeneca US, a United States based Life Sciences organisation with 17535 employees and revenues of $17.74 billion, Boehringer Ingelheim USA, a United States based Life Sciences organisation with 13248 employees and revenues of $14.44 billion, Takeda Pharmaceuticals USA, a United States based Manufacturing organisation with 19500 employees and revenues of $11.83 billion and many others.
Contact us if you need a completed and verified list of companies using Certara D360, including the breakdown by industry (21 Verticals), Geography (Region, Country, State, City), Company Size (Revenue, Employees, Asset) and related IT Decision Makers, Key Stakeholders, business and technology executives responsible for the software purchases.
The Certara D360 customer wins are being incorporated in our Enterprise Applications Buyer Insight and Technographics Customer Database which has over 100 data fields that detail company usage of software systems and their digital transformation initiatives. Apps Run The World wants to become your No. 1 technographic data source!
Apply Filters For Customers
| Logo | Customer | Industry | Empl. | Revenue | Country | Vendor | Application | Category | When | SI | Insight |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Agios Pharmaceuticals | Life Sciences | 536 | $125M | United States | Certara | Certara D360 | Laboratory Management | 2014 | n/a |
In 2014, Agios Pharmaceuticals implemented Certara D360 as a Laboratory Management application to support discovery and preclinical research functions. Agios Pharmaceuticals using Certara D360 as Laboratory Management provided scientists with on demand access to drug discovery and development data across studies, enabling query, analysis, and visualization workflows without constant IT support.
Certara D360 was configured to provide integrated query, analysis, and visualization capabilities, with searchable cross study data views and access to historical control data that are typical requirements for preclinical research. The Certara D360 implementation emphasized self service data access for bench scientists, reducing the need for manual review of multiple study reports and streamlining scientific decision making in discovery and preclinical groups.
Operational coverage centered on discovery and preclinical research departments, where Certara D360 enabled rapid assembly of cross study evidence to answer regulatory questions. The deployment supported scientists in generating on demand reports and visualizations to respond to regulatory agencies, shortening the time required to retrieve cross study information and avoiding costly delays in approval processes.
Governance and workflow changes focused on shifting manual report collation into governed, on demand data queries and standardized analysis workflows. By embedding Certara D360 into lab operations, Agios Pharmaceuticals formalized data access controls and analytic patterns used by research teams, improving the consistency of responses to regulatory inquiries and accelerating go no go decisions in early development.
|
|
|
Arvinas | Life Sciences | 280 | $46M | United States | Certara | Certara D360 | Laboratory Management | 2020 | n/a |
In 2020, Arvinas implemented Certara D360 as a Laboratory Management solution to advance the speed and efficiency of discovery research. The deployment targeted discovery research workflows, consolidating study data and operational processes used by bench scientists and research project teams within the organization.
Certara D360 was configured to deliver category-aligned capabilities including assay workflow orchestration, sample and inventory tracking, study data capture and management, and role based data access for research governance. The implementation focused on standardizing laboratory workflows and centralizing discovery data to support reproducible study execution, while aligning electronic lab procedures and access controls with research governance needs.
|
|
|
AstraZeneca US | Life Sciences | 17535 | $17.7B | United States | Certara | Certara D360 | Laboratory Management | 2014 | n/a |
In 2014, AstraZeneca US implemented Certara D360 as a Laboratory Management application to consolidate laboratory and assay informatics workflows across R&D functions. The Certara D360 deployment was positioned to support discovery chemistry, DMPK assay handling, and clinical study data capture used by clinical study teams and site selection and monitoring analysis groups.
The implementation emphasized laboratory data management capabilities, including standardized assay and chemistry data capture, metadata management for study and protocol elements, and support for master data entity catalog efforts that documented entities, data types, affiliated systems and FAIR status. Configuration work focused on instrument and assay result onboarding, assay metadata templates, and role based access for bench scientists and informatics users.
Operational integration linked Certara D360 into AstraZeneca US informatics and analytics tooling, operating alongside visualization and analytics tools such as SpotFire and Pipeline Pilot, ETL pipelines built with Informatica PowerCenter, and site data held in Oracle databases and in-house applications including Activity Base and Assay Explorer. Backend architecture work included designing connectors and processes to incorporate study data from external sources and to feed downstream analytics and reporting systems.
Governance and adoption activities included targeted training for scientists on Certara D360, process optimization exercises with DMPK teams to standardize workflows, and the creation of documented business processes and validated system artifacts to support regulated R&D use. The rollout prioritized harmonized data capture for site feasibility and patient recruitment estimates, and local informatics teams coordinated configuration and user enablement across discovery and clinical groups.
|
|
|
Blacksmith Medicines | Life Sciences | 11 | $3M | United States | Certara | Certara D360 | Laboratory Management | 2020 | n/a |
In 2020, Blacksmith Medicines implemented Certara D360 as its laboratory informatics hub. Certara D360 Laboratory Management was provisioned to centralize compound and experimental data for Platform Sciences in San Diego, supporting a four person design team and one part time crystallography contractor.
The Certara D360 deployment focused on compound and data management capabilities, configured to capture biochemical and biophysical assay results, DMPK data, and crystallography coordinate and structure interpretation files. The platform was used alongside in house computational modeling workflows, with company scientists identified as power users of Certara D360 and the MOE platform to correlate structure activity relationships and guide iterative design build test cycles.
Integrations included an AWS hosted database that replaced prior Excel based tracking, with Certara D360 serving as the informatics hub for that cloud data store. Operational scope covered Platform Sciences workstreams for inhibitor design, DMPK analysis, assay data production, and structural biology, with the Associate Director of Platform Sciences acting as the primary data steward and company power user for Certara D360.
Governance and workflow changes emphasized centralized data stewardship, single source compound tracking, and structured SAR capture to support cross functional decision making. Certara D360 was explicitly used to link in vitro DMPK and activity data with structural insights to inform subsequent inhibitor optimization and prioritization decisions.
|
|
|
Boehringer Ingelheim | Life Sciences | 54500 | $28.9B | Germany | Certara | Certara D360 | Laboratory Management | 2013 | n/a |
In 2013, Boehringer Ingelheim implemented Certara D360 as its global drug discovery platform. Certara D360 is positioned as an integrated Laboratory Management solution that provides query, analysis and visualization of drug discovery and development data.
D360 permits chemical structure and related biological property data to be shared between global sites, offering data mining, query and visualization capabilities to support cross-site discovery workflows and collaboration. The Certara D360 implementation emphasizes shared access for global working groups and the ability to include external collaborators in discovery data exchange.
Boehringer Ingelheim planned installations of Certara D360 at three sites, Ridgefield CT, Biberach Germany, and Vienna Austria, addressing a landscape where each site was using different data sources, mining tools and workflows. The deployment’s operational scope targets R&D and discovery functions across those sites to provide a common data mining layer and standardized access to discovery datasets.
Rollout and governance focus on exposing existing site data sources into the Certara D360 platform while establishing shared data models and access controls to manage cross-site collaboration. The implementation narrative centers on enabling centralized Laboratory Management capabilities for chemical and biological property data to support global drug discovery decision making.
|
|
|
|
Life Sciences | 13248 | $14.4B | United States | Certara | Certara D360 | Laboratory Management | 2013 | n/a |
|
|
|
|
Life Sciences | 2500 | $1.1B | United States | Certara | Certara D360 | Laboratory Management | 2015 | n/a |
|
|
|
|
Healthcare | 2400 | $600M | United States | Certara | Certara D360 | Laboratory Management | 2022 | n/a |
|
|
|
|
Life Sciences | 6000 | $1.5B | Denmark | Certara | Certara D360 | Laboratory Management | 2020 | n/a |
|
|
|
|
Life Sciences | 120 | $10M | United States | Certara | Certara D360 | Laboratory Management | 2020 | n/a |
|
Buyer Intent: Companies Evaluating Certara D360
- Astorg, a Luxembourg based Banking and Financial Services organization with 170 Employees
Discover Software Buyers actively Evaluating Enterprise Applications
| Logo | Company | Industry | Employees | Revenue | Country | Evaluated |
|---|---|---|---|---|---|---|
| Astorg | Banking and Financial Services | 170 | $200M | Luxembourg | 2026-02-18 |